Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study
Rattachement africain : tr, gb, mm. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) cancer are associated with a poor prognosis. Recent advancements in treatment have incorporated trastuzumab, anti-PD-1 agents, and anti-claudin therapies alongside chemotherapy (ChT), significantly improving outcomes. Contemporary studies predominantly employ doublet ChT as the backbone for these regimens, although historically triplet ChT regimens have been favored, particularly in younger patients requiring rapid tumor shrinkage. Objective: The aim of this study was to compare the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of advanced GC and GEJ adenocarcinoma. Design: This was a retrospective multicenter study. Methods: Patient data were obtained from the databases of 25 hospitals across Turkey. Demographic and clinicopathological characteristics were documented. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan–Meier method, and group discrepancies were assessed with log-rank test. Results: A total of 493 patients were included in the analysis, with similar baseline characteristics between the two groups. The objective response rate was 36.3% in the mDCF group and 38% in the mFOLFOX-6 group ( p = 0.7). The median PFS was 6 months for mDCF and 7 months for mFOLFOX-6 ( p = 0.2), while the median OS was 12 months for mDCF and 11 months for mFOLFOX-6 ( p = 0.4). Grade 3–4 neutropenia occurred in 27.6% of patients treated with mDCF versus 17.8% with mFOLFOX-6 ( p = 0.01). Likewise, grade 3–4 anemia was more frequent in the mDCF group (9.5%) compared to the mFOLFOX-6 group (4.8%; p = 0.04). Conclusion: Modified FOLFOX-6 demonstrated comparable efficacy to mDCF in the treatment of advanced GC and GEJ adenocarcinoma. Moreover, mFOLFOX-6 was associated with a lower incidence of hematological adverse effects.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study
- Date Crossref
- 01/08/2025
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Harran University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Dicle University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Van Yüzüncü Yıl Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
-
Sağlık Bilimleri Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
-
Afyon Kocatepe University pays non établi dans la noticeUniversité ou école supérieure
-
Sakarya Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Bezmiâlem Vakıf Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
-
Dokuz Eylül University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Fırat University pays non établi dans la noticeUniversité ou école supérieure
-
Ümraniye Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Pamukkale University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
State Hospital Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
Department of Medical Oncology — Harran University, Department of Medical Oncology — Dicle University et Van Yüzüncü Yıl Üniversitesi, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.